These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 19048841

  • 1. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].
    Maev IV, Samsonov AA, Golubev NN.
    Klin Med (Mosk); 2008; 86(9):57-63. PubMed ID: 19048841
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
    Karateev AE, Nasonov EL, Radenska-Lopovok SG.
    Ter Arkh; 2005; 77(2):46-9. PubMed ID: 15807452
    [Abstract] [Full Text] [Related]

  • 3. [Effect of bismuth salts in elimination of Helicobacter pylori from gastric mucosa in patients with duodenal ulcer].
    Romańczyk T, Nowakowska-Duława E, Nowakowska M, Rogala-Zawada D, Kłuciński P.
    Med Dosw Mikrobiol; 1993; 45(2):209-12. PubMed ID: 8309299
    [Abstract] [Full Text] [Related]

  • 4. Site-and cytoprotective drugs in the short-term treatment of peptic ulcer. What is their current role?
    Bianchi Porro G, Parente F.
    Ital J Gastroenterol; 1990; 22 Suppl 1():5-10. PubMed ID: 1983422
    [Abstract] [Full Text] [Related]

  • 5. [De-nol in NSAID-induced gastroduodenal lesions].
    Cataldo MG, D'Aiuto A, Bongiorno A.
    Minerva Dietol Gastroenterol; 1990; 36(1):27-30. PubMed ID: 2186304
    [Abstract] [Full Text] [Related]

  • 6. Present and future treatment of peptic ulcer and potential role of DE-NOL.
    Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
    [No Abstract] [Full Text] [Related]

  • 7. [Morphology of the gastric mucosa in patients with duodenal ulcer treated with bismuth-containing drugs].
    Mach T.
    Folia Med Cracov; 1995; 36(1-4):53-75. PubMed ID: 8834668
    [Abstract] [Full Text] [Related]

  • 8. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W.
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [Abstract] [Full Text] [Related]

  • 9. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
    Iakovenko EP, Agafonova NA, Pokhal'skaia OIu, Kolganova AV, Nazarbekova RS, Ivanov AN, Davletshina IV, Popova EV, Prianishnikova AS, Ovchinnikova NI, Iakovenko AV, Aldiiarova MA, D'iachkoava AV, Gioeva IZ.
    Klin Med (Mosk); 2008 Sep; 86(10):47-52. PubMed ID: 19069460
    [Abstract] [Full Text] [Related]

  • 10. A comparative dynamic study of the effectiveness of gastric cytoprotection by vitamin A, De-Nol, sucralfate and ulcer healing by pirenzepine in patients with chronic gastric ulcer (a multiclinical and randomized study).
    Patty I, Tárnok F, Simon L, Jávor T, Deák G, Benedek S, Kenéz P, Nagy L, Mózsik G.
    Acta Physiol Hung; 1984 Sep; 64(3-4):379-84. PubMed ID: 6397969
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS, Marshall BJ, Blackbourn SJ, Warren JR, Phillips M.
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Current methods of ulcer therapy and their efficacy and cost].
    Grigor'ev PIa, Iakovenko EP, Soluianova IP, Abdulzhapparova MA, Talanova EV, Usankova IN, Prianishnikova AS, Agafonova NA, Guliaev PV, Iakovenko AV, Vasil'ev IV, Obukhovskiĭ BI.
    Eksp Klin Gastroenterol; 2003 Jul; (3):21-5, 116. PubMed ID: 14556541
    [Abstract] [Full Text] [Related]

  • 16. A controlled clinical trial with De-Nol (tripotassium dicitrato bismuthate) in patients with gastric ulcer.
    Patty I, Deák G, Jávor T, Mózsik G, Nagy L, Tárnok F.
    Int J Tissue React; 1983 Jul; 5(4):397-401. PubMed ID: 6368445
    [Abstract] [Full Text] [Related]

  • 17. [The role of the polyclinic in raising the efficacy of rehabilitation with peptic ulcer patients].
    Grigor'ev PIa, Iakovenko EP, Prianishnikova AS, Kurdanova VF.
    Ter Arkh; 1992 Jul; 64(1):71-5. PubMed ID: 1523569
    [Abstract] [Full Text] [Related]

  • 18. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN, Nio CY.
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Pharmacotherapy of non-associated with Helicobacter pylori ulcer].
    Grinevich VB, Uspenskiĭ IuP, Shabanova GZh, Sablin OA, Shcherbina NN.
    Klin Med (Mosk); 2002 Aug; 80(10):44-6. PubMed ID: 12471838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.